Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Sanofi”

Phase II Trial to Assess FOLFIRI+Aflibercept Efficacy in Patients With Oxaliplatin-pretreated Metastatic Colorectal Cancer With or Without ACE PolymorphismsCompleted
NCT02970916Phase 2Updated Apr 11, 2019
Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Metastatic Colorectal Cancer
Spain
GM-CSF for Maintenance of Prostate Cancer for Patients Responding to TaxotereCompleted
NCT00274287Phase 2Updated Mar 28, 2019
Sponsor: Oncology Specialists, S.C.
Prostate Cancer
United States
Passive Enhanced Safety Surveillance of Stamaril® Vaccine in KoreaCompleted
NCT03541694N/AUpdated Mar 26, 2019
Sponsor: Sanofi Pasteur, a Sanofi Company
Yellow Fever
South Korea
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With AlirocumabCompleted
NCT01663402Phase 3Updated Mar 18, 2019
Sponsor: Sanofi
Atherosclerotic Cardiovascular Disease
United States, Argentina, Australia, Austria, Belgium +52 more
A Study to Compare the Effectiveness of a Drug That Suppresses the Immune System Called Thymoglobulin® in Preventing the Development of a Disease That Affects the Majority of Heart Transplant Recipients Called Cardiac Allograft Vasculopathy (CAV)Withdrawn
NCT01157949Phase 3Updated Mar 14, 2019
Sponsor: Cedars-Sinai Medical Center
Cardiac Allograft Vasculopathy
United States
Efficacy and Safety of ALX-0171 in Adult Hematopoietic Stem Cell Transplant (HSCT) Recipients Who Present With Respiratory Syncytial Virus (RSV) InfectionWithdrawn
NCT03468829Phase 2Updated Mar 11, 2019
Sponsor: Ablynx, a Sanofi company
Respiratory Syncytial Virus Lower Respiratory Tract Infection
Australia, Belgium, Spain
Clopidogrel For the Prevention of New Onset Migraine Headache Following Transcatheter Closure of Atrial Septal DefectsCompleted
NCT00799045Phase 4Updated Feb 26, 2019
Sponsor: Laval University
Migraine
Canada
A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus ErythematosusCompleted
NCT02437890Phase 2Updated Feb 26, 2019
Sponsor: Ablynx, a Sanofi company
Lupus Erythematosus, Systemic
United States, Argentina, Chile, Czechia, Germany +12 more
Investigating Pompe Prevalence in Neuromuscular Medicine Academic PracticesCompleted
NCT02838368N/AUpdated Feb 25, 2019
Sponsor: University of California, Irvine
Pompe Disease
United States
First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer.Completed
NCT01129310Phase 2Updated Feb 25, 2019
Sponsor: AHS Cancer Control Alberta
Gastrointestinal Neoplasm · Gastric Adenocarcinoma
Canada
Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)Completed
NCT01839188Phase 3Updated Feb 25, 2019
Sponsor: MCM Vaccines B.V.
Neisseria Meningitidis · Bacterial Infections · Virus Diseases
Pilot Study Evaluating Doxercalciferol Replacement Therapy in Kidney Transplant RecipientsCompleted
NCT00889629Phase 4Updated Feb 22, 2019
Sponsor: Mariana Markell
Chronic Kidney Disease · Kidney Transplantation
United States
Induction CT by Cisplatin, 5FU With or Without Docetaxel in Patients With T3 and T4 Larynx and Hypopharynx CarcinomaCompleted
NCT00169182Phase 3Updated Feb 15, 2019
Sponsor: Groupe Oncologie Radiotherapie Tete et Cou
Larynx Cancer · Hypopharynx Cancer
France
INTEGRA Study: Primary Care Intervention in Type 2 Diabetes Patients With Poor Glycaemic ControlCompleted
NCT02663245NAUpdated Feb 15, 2019
Sponsor: Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Type 2 Diabetes Mellitus
Spain
Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction CarcinomaTerminated
NCT00256321Phase 2Updated Feb 8, 2019
Sponsor: University of California, Irvine
Gastric Carcinoma · Gastroesophageal Junction Carcinoma
United States
Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis Fungoides or Sézary SyndromeCompleted
NCT00057967Phase 2Updated Feb 6, 2019
Sponsor: Northwestern University
Lymphoma
United States
Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of StatinCompleted
NCT02584504Phase 3Updated Jan 23, 2019
Sponsor: Sanofi
Hypercholesterolemia
Japan
Cyclophosphamide and Alemtuzumab In LymphomaTerminated
NCT03132584Phase 1Updated Jan 14, 2019
Sponsor: Dana-Farber Cancer Institute
Non Hodgkin Lymphoma · High-grade B-cell Lymphoma · Diffuse Large B Cell Lymphoma
United States
HSV529 Vaccine in HSV-2 Seropositive AdultsCompleted
NCT02571166Phase 1Updated Jan 14, 2019
Sponsor: Fred Hutchinson Cancer Center
Herpes Simplex Virus 2
United States
A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in TurkeyCompleted
NCT02954692Phase 4Updated Jan 14, 2019
Sponsor: Sanofi
Type 2 Diabetes Mellitus
Turkey (Türkiye)
A Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With RSV Lower Respiratory Tract Infection to Evaluate the Safety, Tolerability, and Clinical Activity of ALX-0171Completed
NCT02309320Phase 1, Phase 2Updated Jan 10, 2019
Sponsor: Ablynx, a Sanofi company
Respiratory Syncytial Virus Infection
Australia, Belgium, Bulgaria, Estonia, Hungary +9 more
Study to Assess Safety and Efficacy of Anti-Interleukin 6-receptor (IL6R) Nanobody in Rheumatoid Arthritis (RA) PatientsCompleted
NCT01284569Phase 1, Phase 2Updated Jan 4, 2019
Sponsor: Ablynx, a Sanofi company
Rheumatoid Arthritis
Czechia, Hungary, Poland
ALX-0061 Phase I Bioavailability Study in Healthy VolunteersCompleted
NCT02101073Phase 1Updated Jan 4, 2019
Sponsor: Ablynx, a Sanofi company
Rheumatoid Arthritis
Netherlands
Allergy to Neuromuscular Blocking Agents and Pholcodine ExposureUnknown
NCT02250729NAUpdated Dec 27, 2018
Sponsor: Central Hospital, Nancy, France
Neuromuscular Blocking Agents Anaphylaxis
France
Study of Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REGN3500 in Adults With Moderate AsthmaCompleted
NCT02999711Phase 1Updated Dec 12, 2018
Sponsor: Regeneron Pharmaceuticals
Asthma · Moderate Asthma
United Kingdom

Previous page Next page